KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Quest Diagnostics (DGX) EBITDA Margin (2016 - 2025)

Quest Diagnostics' EBITDA Margin history spans 17 years, with the latest figure at 13.76% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 2.0% year-over-year to 13.76%; the TTM value through Dec 2025 reached 14.1%, up 47.0%, while the annual FY2025 figure was 14.1%, 47.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 13.76% at Quest Diagnostics, roughly flat from 13.71% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 24.26% in Q1 2021 and bottomed at 5.79% in Q4 2022.
  • The 5-year median for EBITDA Margin is 14.85% (2024), against an average of 15.53%.
  • The largest annual shift saw EBITDA Margin skyrocketed 1466bps in 2021 before it plummeted -1375bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 19.53% in 2021, then crashed by -70bps to 5.79% in 2022, then soared by 102bps to 11.67% in 2023, then increased by 18bps to 13.77% in 2024, then fell by 0bps to 13.76% in 2025.
  • Per Business Quant, the three most recent readings for DGX's EBITDA Margin are 13.76% (Q4 2025), 13.71% (Q3 2025), and 15.86% (Q2 2025).